Eli Lilly elects Dr. Mary Lynne Hedley to board effective May 15, 2022

ELI LILLY & Co

Dr. Mary Lynne Hedley elected to Lilly's Board of Directors, effective May 15, 2022.
She will serve on the Science & Technology Committee and the Ethics and Compliance Committee.
Hedley is a Senior Scientific Fellow at Broad Institute; previously co-founded TESARO (acquired by GSK) and served as President/COO.
Board determined she is independent under NYSE standards and company guidelines.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Mary Lynne Hedley

Director

LLY · ELI LILLY & Co

Effective: 2022-05-15
Filed: May 6, 2022, 7:59 PM ET

On May 2, 2022, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Dr. Mary Lynne Hedley as a new member of the class of 2025, effective May 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Mary Lynne Hedley was elected as Director at ELI LILLY & Co.

Action: elected
Role: Director

Exact text from the filing

On May 2, 2022, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Dr. Mary Lynne Hedley as a new member of the class of 2025, effective May 15, 2022.

View on SEC.gov

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-22-000143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.